Goal: The successful completion of this study will improve our understanding of the genetic markers associated with severe acne and the adverse response to oral isotretinoin (Accutane) treatment, leading to the development of safer and more effective treatments.
Eligibility Requirements: understand and give written consent (adult) and assent (child); demonstrate a current or previous diagnosis (12-18 years of age) of severe acne vulgaris and have received oral isotretinoin treatment (eg. Accutane, Amnesteem, Claravis, Sotret). *Geographic criteria are waived for this study
Study Requirements: blood and urine sample; a medical questionnaire about general health and a second questionnaire pertaining to acne diagnosis and treatment
Compensation: compensation will be provided for time and travel
Enrollment Goal: 250 participants
Current Enrollment: 122
Principal Investigator: Dr. Russell Hall (interim)
Media:
- Severe Acne Press Release – January 2012
- New Study Could Bring Relief to Acne Patients, TWC – February 2012
- MURDOCK Study seeks people with acne – May 2012
